Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial

Figures & data

Table 1 Demographic characteristics of studied groups

	Together (n = 96)	od Betaxolol (n = 47)	bd Metoprolol (n = 49)	P
Age (mean ± SD)	56.8 ± 9.9	58.5 ± 9.9	55.0 ± 9.6	ns
Male (%)	40.6	34.0	46.9	ns
Number of monitored days (mean ± SD)	66.0 ± 16.4	65.6 ± 11.8	66.3 ± 19.9	ns

ns = p > 0.05

Table 2 Parameters of patient compliance in studied groups (parameters are expressed as mean ± SD)

Parameter	od Betaxolol (n = 47)	bd Metoprolol (n = 49)	p
Overall compliance (%)	86.5 ± 21.3	76.1 ± 26.3	0.002
Days with correct number of doses taken (%)	84.4 ± 21.6	64.0 ± 31.7	<0.0001
Days with no dose (%)	14.5 ± 21.4	15.2 ± 24.2	ns
Days with extra doses (%)	1.0 ± 1.2	1.6 ± 2.6	ns
Missing doses (%)	14.5 ± 21.5	24.8 ± 26.4	0.004
Doses taken in correct time window (%)	58.6 ± 31.9	42.0 ± 28.0	0.01
Correct interdose intervals (%)	77.4 ± 26.6	53.1 ± 32.5	<0.0001
Therapeutic coverage (%)	85.6 ± 21.2	73.7 ± 25.8	0.0005
Pill count (%)	94.8 ± 16.2	88.8 ± 24.7	ns

ns = p > 0.05

Figure 1 The changes in weekly number of chest pain episodes and additional short-acting nitrates taken in case of need with time in studied groups.Two initial weeks constitute baseline period.

Table 3 EQ-5D dimension scores and visual analog health scale (VAS) scores at randomization (V0) and the final visit (V8)

Dimension	V0		V8
	Betaxolol (n = 47)	Metoprolol (n = 49)	Betaxolol (n = 47)	Metoprolol (n = 49)
Mobility
No difficulties (%)	73.9	69.4	86.4	71.4
Some difficulties (%)	26.1	28.6	13.6	26.5
Extreme difficulties (%)	0	2.0	0	2.0
Self-care
No difficulties (%)	91.3	93.9	95.5	89.8
Some difficulties (%)	8.7	6.1	4.5	10.2
Extreme difficulties (%)	0	0	0	0
Usual activities
No difficulties (%)	76.1	71.4	81.8	81.6
Some difficulties (%)	23.9	28.6	18.2	18.4
Extreme difficulties (%)	0	0	0	0
Pain/discomfort
No difficulties (%)	26.1d	18.4d	72.7d	57.1d
Some difficulties (%)	73.9d	81.6d	27.3d	42.9d
Extreme difficulties (%)	0	0	0	0
Anxiety/depression
No difficulties (%)	41.3b	38.8c	63.4b	69.4c
Some difficulties (%)	58.7b	61.2c	36.4b	30.6c
Extreme difficulties (%)	0	0	0	0
Mean EQ-5D utility	1.38 ± 0.49a	1.42 ± 0.50b	1.20 ± 0.40a	1.27 ± 0.45b
Mean EQ-5D VAS	63.3 ± 14.0d	63.1 ± 15.6d	75.8 ± 13.0d	75.0 ± 10.9d

a p = 0.05 between V0 and V8,

b p < 0.05 between V0 and V8,

c p < 0.01 between V0 and V8,

d p < 0.001 between V0 and V8.

Table 4 Changes to the quality of life dimensions after 8 weeks of active treatment

Dimension	Final visit
	Betaxolol (n = 42)a(%)	Metoprolol (n = 46)(%)
General well-being
Improved (%)	73.2	71.7
No change (%)	24.4	28.3
Deteriorated (%)	2.4	0.0
Sleep
Improved	31.0	34.8
No change	66.7	65.2
Deteriorated	2.4	0.0
Mood
Improved	42.9	37.0
No change	52.4	60.9
Deteriorated	4.8	2.2
Psychical function
Improved	19.0	13.0
No change	78.6	87.0
Deteriorated	2.4	0.0
Physical function
Improved	42.9b	15.2b
No change	57.1b	84.8b
Deteriorated	0.0	0.0
Sexual function
Improved	0.0	4.3
No change	100.0	95.7
Deteriorated	0.0	0.0

a for General well-being n = 41,

b p < 0.01 between two groups.